Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make an assessment of the implications for her policies of trends in the level of the availability of Elvanse medication.

It is the responsibility of integrated care boards (ICBs) to make available appropriate provision, including for attention deficit hyperactivity disorder (ADHD) assessment and support, to meet the health and care needs of their local population, in line with relevant National Institute for Health and Care Excellence (NICE) guidelines. NICE guidelines for ADHD diagnosis and management aim to improve the diagnosis of ADHD and the quality of care and support people receive. The Department is looking into options for improving data collection and reporting on ADHD assessment waiting times, to help improve access to ADHD assessments in a timely way and in line with the NICE guidelines.

Disruptions to the supply of medicines used for the management of ADHD, including Lisdexamfetamine (Elvanse), have been primarily driven by issues which have resulted in capacity constraints at key manufacturing sites. The Department has been working closely with the respective manufacturers and some issues have now been resolved. However, we know that there continue to be disruptions to the supply of some other medicines, which should resolve by April 2024.